{"title":"SGLT-2抑制剂对糖尿病和心力衰竭患者肝僵硬的影响：一项纤维扫描研究","authors":"Huseyin Ali Ozturk, Hilmi Erdem Sumbul","doi":"10.1007/s11845-025-04087-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure.</p><p><strong>Methods: </strong>In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).</p><p><strong>Results: </strong>NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).</p><p><strong>Conclusion: </strong>Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.</p>","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study.\",\"authors\":\"Huseyin Ali Ozturk, Hilmi Erdem Sumbul\",\"doi\":\"10.1007/s11845-025-04087-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure.</p><p><strong>Methods: </strong>In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).</p><p><strong>Results: </strong>NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).</p><p><strong>Conclusion: </strong>Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.</p>\",\"PeriodicalId\":14507,\"journal\":{\"name\":\"Irish Journal of Medical Science\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Irish Journal of Medical Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11845-025-04087-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-025-04087-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study.
Aim: Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure.
Methods: In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).
Results: NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).
Conclusion: Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.
期刊介绍：
The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker.
The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
